LSB Stock Overview
A biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LakeShore Biopharma Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.96 |
| 52 Week High | US$11.20 |
| 52 Week Low | US$1.88 |
| Beta | 0.83 |
| 1 Month Change | 12.98% |
| 3 Month Change | -61.61% |
| 1 Year Change | -47.61% |
| 3 Year Change | -95.65% |
| 5 Year Change | n/a |
| Change since IPO | -95.54% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%
Nov 01
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough
Jun 25Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues
May 08Shareholder Returns
| LSB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.6% | -3.6% | -2.4% |
| 1Y | -47.6% | -2.6% | 23.4% |
Return vs Industry: LSB underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: LSB underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| LSB volatility | |
|---|---|
| LSB Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LSB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LSB's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 758 | Wang Xu | www.ysbiopharm.com |
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines.
LakeShore Biopharma Co., Ltd Fundamentals Summary
| LSB fundamental statistics | |
|---|---|
| Market cap | US$56.48m |
| Earnings (TTM) | -US$59.41m |
| Revenue (TTM) | US$78.59m |
0.7x
P/S Ratio-1.0x
P/E RatioIs LSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSB income statement (TTM) | |
|---|---|
| Revenue | CN¥573.42m |
| Cost of Revenue | CN¥187.36m |
| Gross Profit | CN¥386.06m |
| Other Expenses | CN¥819.52m |
| Earnings | -CN¥433.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.72 |
| Gross Margin | 67.33% |
| Net Profit Margin | -75.59% |
| Debt/Equity Ratio | 71.3% |
How did LSB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:37 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LakeShore Biopharma Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hunter Diamond | Diamond Equity Research LLC |
| Gregory Aurand | NOBLE Capital Markets, Inc. |